방사성 옥소치료에 내성을 가진 분화 갑상선암의 진단 및 치료적 접근
Diagnostic and Therapeutic Approaches to Radioactive Iodine Refractory Differentiated Thyroid Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Unlike most thyroid cancers which have an excellent prognosis with standard treatments such as surgery and additional radioactive iodine therapy followed by long term TSH suppression, 15-20% of differentiated thyroid cancers are unresponsive, showing locally aggressive behavior or distant metastasis. It has been reported that the ability of iodine uptake among residual follicular cells is usually impaired in such unresponsive cases. As the general incidence of thyroid cancer increases, the number of this radioactive iodine refractory disease is also increasing. This becomes clinically challenging because iodine-based diagnostic and therapeutic approaches are not applicable anymore. Moreover, other conventional modalities including radiotherapy or cytotoxic chemotherapy is neither effective in this subset of thyroid cancer. So many researches are currently under way to find effective molecular targeted therapies, which will play a role in the treatment of these unresectable and advanced cases. This review discusses the recent research progress regarding the iodine avidity of follicular cells in thyroid cancer, and outcomes of clinical studies using targeted agents.
Abstract
Unlike most thyroid cancers which have an excellent prognosis with standard treatments such as surgery and additional radioactive iodine therapy followed by long term TSH suppression, 15-20% of differentiated thyroid cancers are unresponsive, showing locally aggressive behavior or distant metastasis. It has been reported that the ability of iodine uptake among residual follicular cells is usually impaired in such unresponsive cases. As the general incidence of thyroid cancer increases, the number of this radioactive iodine refractory disease is also increasing. This becomes clinically challenging because iodine-based diagnostic and therapeutic approaches are not applicable anymore. Moreover, other conventional modalities including radiotherapy or cytotoxic chemotherapy is neither effective in this subset of thyroid cancer. So many researches are currently under way to find effective molecular targeted therapies, which will play a role in the treatment of these unresectable and advanced cases. This review discusses the recent research progress regarding the iodine avidity of follicular cells in thyroid cancer, and outcomes of clinical studies using targeted agents.
참고문헌 (45)
- National Cancer Center, Ministry of Health & Welfare, "Cancer Facts & Figures 2011 in the Republic of Korea", pp.6~21 (2011), Seoul, Republic of Korea 2011
- Eustatia-Rutten CF, "Survival and death causes in differentiated thyroid carcinoma", J Clin Endocrinol Metab, 91(1), pp.313~319 (2006)
- Schlumberger M, "Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances", Thyroid, 19(12), pp.1393~1400 (2009)
- Durante C, "Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy", J Clin Endocrinol Metab, 91(8), pp.2892~2899 (2006)
- Mihailovic J, "The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases", Thyroid, 19(3), pp.227~232 (2009)
- Ronga G, "Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience", Q J Nucl Med Mol Imaging, 48(1), pp.12~19 (2004)
- Nikiforov YE, "Diagnostic pathology and molecular genetics of the thyroid. 1st ed", pp.29~ (2009), Lippincott Williams & Wilkins
- Russo D, "Absence of sodium", iodide symporter gene mutations in differentiated human thyroid carcinomas, 2001, pp.11(1), 37~39
- Wapnir IL, "Immunohistochemical profile of the sodium", iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections, 2003, pp.88(4), 1880~1888
- Wang ZF, "Expression and correlation of sodium", iodide symporter and thyroid stimulating hormone receptor in human thyroid carcinoma, 2011, pp.97(4), 540~546
- Caillou B, "Na+", I- symporter distribution in human thyroid tissues: an immunohistochemical study, 1998, pp.83(11), 4102~4106
- Faggiano A, "Functional characterization of human thyroid tissue with immunohistochemistry", Thyroid, 17(3), pp.203~211 (2007)
- Morari EC, "Use of sodium iodide symporter expression in differentiated thyroid carcinomas", Clin Endocrinol (Oxf), 75(2), pp.247~254 (2011)
- Smith VE, "A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer", J Cell Sci, 122(Pt 18), pp.3393~3402 (2009)
- SodréAK, "Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining", J Clin Endocrinol Metab, 93(10), pp.4141~4145 (2008)
- Trouttet-Masson S, "Evidence for transcriptional and posttranscriptional alterations of the sodium", iodide symporter expression in hypofunctioning benign and malignant thyroid tumors, 2004, pp.165(1), 25~34
- Neumann S, "Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules", Thyroid, 14(2), pp.99~111 (2004)
- Castro MR, "Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake", J Clin Endocrinol Metab, 86(11), pp.5627~5632 (2001)
- Min JJ, "Relationship between expression of the sodium", iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma, 2001, pp.28(5), 639~645
- Feine U, "Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer", J Nucl Med, 37(9), pp.1468~1472 (1996)
- Grabellus F, "Glucose transporter 1 expression, tumor proliferation, and iodine", glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma, 2012, pp.37(2), 121~127
- Grabellus F, "The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression", Thyroid, 22(4), pp.377~382 (2012)
- Ricarte-Filho JC, "Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1", Cancer Res, 69(11), pp.4885~4893 (2009)
- Saji M, "The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors", Mol Cell Endocrinol, 321(1), pp.20~28 (2010)
- Hoftijzer H, "Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma", Eur J Endocrinol, 161(6), pp.923~931 (2009)
- Fenton MS, "Sunitinib inhibits MEK", ERK and SAPK, iodide symporter expression in papillary thyroid cancer, pp.Thyroid, 2010[DOI]
- Bachelot A, "Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment", Clin Endocrinol (Oxf), 62(3), pp.376~379 (2005)
- fluoro-2-deoxy-D-glucose-positron emission tomography scanning, "J Clin Endocrinol Metab", 2006, 498~505
- Moog F, "Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma", J Nucl Med, 41(12), pp.1989~1995 (2000)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45(2), pp.228~247 (2009)
- "Thyroid Carcinoma. version 2/URL:" (2012)[URL]
- Pacini F, "Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients", J Clin Endocrinol Metab, 86(9), pp.4092~4097 (2001)
- Sawka AM, "Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta- analysis", Thyroid, 19(5), pp.451~457 (2009)
- Shepler TR, "Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma", Ophthal Plast Reconstr Surg, 19(6), pp.479~481 (2003)
- Schlumberger M, "Approach to the patient with advanced differentiated thyroid cancer", Eur J Endocrinol, 166(1), pp.5~11 (2012)
- Sherman SI, "Motesanib diphosphate in progressive differentiated thyroid cancer", N Engl J Med, 359(1), pp.31~42 (2008)
- Bass MB, "Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer", J Clin Endocrinol Metab, 95(11), pp.5018~5027 (2010)
- Cohen EE, "Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study", J Clin Oncol, 26(29), pp.4708~4713 (2008)
- Kloos RT, "Phase II trial of sorafenib in metastatic thyroid cancer", J Clin Oncol, 27(10), pp.1675~1684 (2009)
- Gupta-Abramson V, "Phase II trial of sorafenib in advanced thyroid cancer", J Clin Oncol, 26(29), pp.4714~4719 (2008)
- Brose MS, "Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer", BMC Cancer, 11, pp.349~ (2011)
- Bible KC, "Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study", Lancet Oncol, 11(10), pp.962~972 (2010)
- Carr LL, "Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation", Clin Cancer Res, 16(21), pp.5260~5268 (2010)
- Sherman SI, "ASCO presentation", ~ (2011)
- Hayes DN, "Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244 ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements", Clin Cancer Res, 18(7), pp.2056~2065 (2012)